Antiviral therapy against HIV infection.
The replication of human immunodeficiency virus (HIV) can be suppressed in vivo by drugs chosen on the basis of their selective in vitro antiviral activity. Such suppression can confer prolonged survival and improved quality of life in patients with already established HIV infection. The clinical benefits indicate that targeted therapy for acquired immunodeficiency syndrome based on the emerging knowledge of replicative cycle of HIV is an attainable goal.
Division of Cancer Treatment National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
H
H
Mitsuya
R
R
Yarchoan
S
S
Hayashi
S
S
Broder
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D000998:Antiviral Agents / Q000627:therapeutic use*; D015224:Dideoxynucleosides / Q000627:therapeutic use; D006678:HIV / Q000187:drug effects; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D015215:Zidovudine / Q000627:therapeutic use
D000998:Antiviral Agents; D015224:Dideoxynucleosides; D015215:Zidovudine